Global state: clinically important change in global state · people in the prodromal stage of psychosis
1 finding from 1 review
Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · people in the prodromal stage of psychosis
1 finding from 1 review
Behaviour: clinically important change in behaviour · people in the prodromal stage of psychosis
1 finding from 1 review
Adverse effects: specific ‐ doctors' assessment of adverse effects UKU (events) Medium‐term · people in the prodromal stage of psychosis
It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes adverse effects: doctors' assessment of adverse effects UKU (events)… compared with supportive therapy + placebo (very low certainty).
1 finding from 1 review
Quality of life QLS · people in the prodromal stage of psychosis
1 finding from 1 review
Satisfaction with treatment: leaving the study early Endpoint data (events) · people in the prodromal stage of psychosis
It is very uncertain whether group C cognitive behavioural therapy: cognitive behavioural therapy… changes satisfaction with treatment: leaving the study early Endpoint data… compared with supportive therapy + placebo (very low certainty).
1 finding from 1 review
Overall survival · patients with extensive SCLC without previous treatment
1 finding from 1 review
Adverse effects · patients with extensive SCLC without previous treatment
1 finding from 1 review
Overall survival (absolute effect size estimates based on survival rate at 12 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes overall survival (absolute effect size estimates based on survival… compared with best supportive care alone (very low certainty).
1 finding from 1 review
Proportion of people with ≥ 1 serious adverse events (at 20 months) · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with ≥ 1 serious adverse events (at 20 months) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Health‐related quality of life · participants with advanced hepatocellular carcinoma
1 finding from 1 review
Disease progression · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes proportion of people with disease progression compared with best supportive care alone (very low certainty).
1 finding from 1 review
Adverse events considered non‐serious · participants with advanced hepatocellular carcinoma
It is very uncertain whether pexastimogene devacirepvec (Pexa‐Vec) plus best supportive care changes adverse events considered non‐serious (number of participants) compared with best supportive care alone (very low certainty).
1 finding from 1 review
Intervention not reported
Supportive care only*** (1 RCT, 81 participants) · elderly people with newly diagnosed glioblastoma Interventions: radiotherapy with 40 Gy in 15 fractions (RT40); radiotherapy with 60 Gy in…
1 finding from 1 review
Adjunctive antimicrobial photodynamic therapy (aPDT) applied after submucosal instrumentation (SI) vs Submucosal instrumentation (SI) alone, or SI plus placebo/sham aPDT
Outcome not reported · Adults (> 18 years) with peri-implant mucositis, receiving supportive treatment
The review found no eligible studies for this question.
1 finding from 1 review
Adjunctive antimicrobial photodynamic therapy (aPDT) applied after submucosal instrumentation (SI) vs Submucosal instrumentation (SI) alone, or SI plus placebo/sham aPDT
Outcome not reported · Adults (> 18 years) with peri-implantitis, receiving supportive treatment
The review found no eligible studies for this question.
1 finding from 1 review
Attachment change · Adults (> 18 years) with recurrent periodontitis, receiving supportive (maintenance) periodontal care
It is very uncertain whether adjunctive antimicrobial photodynamic therapy (aPDT) applied after… changes change in clinical attachment level (CAL) compared with subgingival instrumentation (SI) alone (hand or power-driven, or… (very low certainty).
2 findings from 1 review
Change in bleeding on probing (BOP) · Adults (> 18 years) with recurrent periodontitis, receiving supportive (maintenance) periodontal care
Adjunctive antimicrobial photodynamic therapy (aPDT) applied after… showed no clear difference in change in bleeding on probing (BOP) compared with subgingival instrumentation (SI) alone (hand or power-driven, or…; GRADE not reported.
2 findings from 1 review
Change in gingival recession (REC) · Adults (> 18 years) with recurrent periodontitis, receiving supportive (maintenance) periodontal care
It is very uncertain whether adjunctive antimicrobial photodynamic therapy (aPDT) applied after… changes change in gingival recession (REC) compared with subgingival instrumentation (SI) alone (hand or power-driven, or… (very low certainty).
2 findings from 1 review
Pocket closure · Adults (> 18 years) with recurrent periodontitis, receiving supportive (maintenance) periodontal care
2 findings from 1 review
Three studies evaluated the proportion of closed pockets three months after treatment (Campos 2013; Grzech-Lesniak 2019; Ruhling 2010); studies used different criteria to measure this outcome. All studies reported an…
3 studies
GRADE not reported
No studies measured this outcome at 6 months (SoF row labeled 'Change in pocket depth from baseline to 6 months after treatment'); no studies reported these data at six months after treatment.
Studies not reported
No studies found